PDT + MAL Option for Severe Acne

Due to the limited therapeutic options for severe acne vulgaris, researchers D.M. Pariser, MD, et al, investigated a new photodynamic therapy (PDT) treatment protocol using red light and methyl aminolevulinate (MAL).

The double-blind, randomized, vehicle-controlled multicenter trial enrolled 153 patients (aged 12-35 years) with severe facial acne, which was characterized as an Investigator’s...

Articles

PDT + MAL Option for Severe Acne

Due to the limited therapeutic options for severe acne vulgaris, researchers D.M....

Allergan has acquired Topokine Therapeutics, a privately held, clinical-stage...

The Valeant Pharmaceuticals International Board of Directors has named Joseph C. Papa...

Johnson & Johnson is preparing to acquire privately held NeoStrata Company. The...

Products

Barrier Repair

Young Pharmaceuticals MoistuSilc Ultra replenishes the skin’s natural...

Growth Factor Cream

Skinprint Skintellect Micro-Gel Cream stimulates skin receptors to release...

Encapsulated Retinol

SkinMedica Retinol Complex—which addresses photodamage, including fine lines...

Skin Brightening Lotion

Marini Luminate Face Lotion from Jan Marini Skin Research lightens the...

Blogs

Creating Effective Newsletters
By Mara L. Shorr and Jay A. Shorr of Best Medical Business Solutions Each day, your patients’ email inboxes are flooded with e-newsletters and e-blasts craving their attention. Whether they come from daily deal sites, their favorite big box stores or their tried and true online retailers, the sheer...
Setting Expectations for Your Suppliers
By Carol and Rob Trow of Dermaconcepts There are few, if any, more problematic profit issues for aesthetic professionals, practice owners and managers than how to increase retail revenue for their practices. The challenges center on several endemic root causes, which I will discuss below. But it...
PDT + MAL Option for Severe Acne

Due to the limited therapeutic options for severe acne vulgaris, researchers D.M. Pariser, MD, et al, investigated a new photodynamic therapy (PDT) treatment protocol using red light and methyl aminolevulinate (MAL).

The double-blind, randomized, vehicle-controlled multicenter trial enrolled 153 patients (aged 12-35 years) with severe facial acne, which was characterized as an Investigator’s Global Assessment (IGA) score of four; 25-75 inflammatory lesions with ≤ three nodules; and 20-100 non-inflammatory lesions. Topical MAL (80mg-1) was used as the photosensitizer. Treatment (four treatments, two weeks apart) involved incubation with MAL (n = 100) or vehicle cream (n = 53) for 90 minutes under occlusion, then illumination (635nm red light, total dose 37J cm-2). IGA assessment and standardized lesion counts were performed before each treatment and 12 weeks after the first treatment. Treatment success was defined as improvement from baseline in IGA by ≥ two grades at 12 weeks. Safety assessments were for pain (10-cm visual analogue scale immediately after illumination), erythema (four-point rating scale) and adverse events.

At 12 weeks, PDT using MAL reduced inflammatory lesions vs. vehicle...

Allergan Acquires Topokine Therapeutics

Allergan has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Under the terms of the agreement, Allergan purchased Topokine Therapeutics for an up-front payment of $85 million and success-based development and sales milestones for XAF5, Topokine’s topical agent in late-stage development for the treatment of steatoblepharon.

In a Phase 2 clinical trial, XAF5 met the primary endpoint achieving statistically significant and clinically meaningful reductions in undereye bags. In January 2016, Topokine initiated a pivotal Phase 2b/3 study of XAF5.

“XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients. We look forward to continuing the outstanding development work conducted by the Topokine team to bring this innovative medical aesthetic treatment to market,” said David Nicholson, executive vice president and president of Global Brands Research & Development at Allergan.

Valeant Appoints New CEO

The Valeant Pharmaceuticals International Board of Directors has named Joseph C. Papa as the company’s chairman and CEO. He is expected to join Valeant by early May. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain CEO and a director until Papa arrives.

Papa has more than 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries, including 20 years of branded prescription drug experience. He previously served as chairman and CEO of Perrigo Company, a global healthcare supplier that develops, manufactures and distributes over-the-counter and prescription pharmaceuticals. Prior to Perrigo, Papa held positions as chairman and CEO of the Pharmaceutical and Technologies Services segment of Cardinal Health, and president and COO of Watson Pharmaceuticals.

“The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time. He has a strong shareholder orientation, a background in science and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R...

AAD Commends FDA for Indoor Tanning Restrictions

The American Academy of Dermatology (AAD) applauds the U.S. Food and Drug Administration (FDA) for proposing new regulations governing indoor tanning, including an age restriction for minors under the age of 18 as well as a risk-acknowledgement form that all adults must sign before using indoor tanning devices.


According to the AAD, statistics show that millions of people tan indoors annually and the risk of developing melanoma increases by 59% for individuals exposed to UV radiation from indoor tanning—the risk increases with each use. If the FDA’s proposed rule becomes final,... more »

ASDS Honored With 14 MarCom Awards

The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.


The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.


The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »

Cellfina Available in US

Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.


Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »